Biosimilar Antibodies

Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody engineered to specifically bind to both IGF1 and IGF2. This targeted interaction potentially modulates the activity of these growth factors, which are crucial in cellular processes such as growth, development, and metabolism. Dusigitumab is primarily utilized in research focused on the pathophysiology and therapeutic targeting of diseases influenced by IGF signaling.

OS-2966 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Integrin β1 (ITGB1/CD29). This antibody is composed of a human IgG1 type heavy chain and a human kappa (huκ) type light chain. The predicted molecular weight of OS-2966 is approximately 145.5 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended as the appropriate isotype control for OS-2966. This antibody is pivotal for research focused on cell adhesion, migration, and signaling pathways mediated by Integrin β1.

Motavizumab (MEDI-524) is a monoclonal antibody targeted against the human Respiratory Syncytial Virus (RSV). This antibody is specifically designed for research into the prevention and treatment of RSV infections in high-risk infant populations. Motavizumab binds to the F protein of RSV, neutralizing the virus and potentially preventing the viral fusion with host cell membranes, a key step in the viral infection process. This makes it an invaluable tool for studies aimed at understanding and mitigating RSV pathogenesis in susceptible infant groups.

Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody that specifically targets tumor necrosis factor-like ligand 1A (TL1A). This antibody is designed for use in research focused on inflammatory bowel disease, providing a valuable tool for investigating the role of TL1A in inflammation and immune response.

Anti-PCSK9 (RG7652) is a fully human monoclonal antibody of the immunoglobulin G1 (IgG1) subclass, designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody has demonstrated potential efficacy in reducing the risk associated with coronary heart disease (CHD) by modulating lipid metabolism through the inhibition of PCSK9, a key regulator of cholesterol homeostasis. Anti-PCSK9 (RG7652) is suitable for use in research focused on lipid disorders, cardiovascular diseases, and the molecular mechanisms of cholesterol regulation.

Anti-MERS-D12 monoclonal antibody (mAb) is a human IgG1 isotype designed to specifically target the receptor-binding domain (RBD) of the MERS-CoV Spike protein, particularly the DPP4 interacting region. This antibody functions by effectively neutralizing the virus through direct inhibition of receptor binding, thereby preventing viral entry into host cells. Ideal for research focused on viral pathogenesis, therapeutic intervention, and vaccine development against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

The Anti-VEGFR1/FLT1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting VEGFR1/FLT1. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended. This product is pivotal in studies focusing on the modulation and function of VEGFR1/FLT1 in angiogenesis and vascular biology.

Tirnovetmab (KIND-016) is a monoclonal antibody specifically designed for experimental research purposes. This antibody targets key pathways in disease models, offering valuable insights for scientific studies focused on its mechanism of action and potential therapeutic applications.

Micvotabart is a human monoclonal antibody of the IgG1κ isotype that specifically targets fibronectin 1 (FN1). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Arcitumomab is a murine-derived monoclonal antibody fragment (Fab') specifically targeting the carcinoembryonic antigen (CEA). This agent is suitable for conjugation with technetium-99m, facilitating its use in single-photon emission computed tomography (SPECT) imaging to enhance diagnostic accuracy in oncology research.

Alvircept sudotox is a recombinant fusion protein that combines a segment of CD4 with a modified form of Pseudomonas aeruginosa exotoxin A. This biologic is specifically engineered for the study of HIV infections, exploiting the natural affinity of CD4 for the HIV envelope protein to selectively deliver the cytotoxic exotoxin to infected cells. Alvircept sudotox serves as a valuable tool in HIV research, offering potential insights into targeted cytotoxic therapies against HIV-infected cells.

Quilizumab is a humanized IgG1κ monoclonal antibody specifically designed to target immunoglobulin epsilon (IGHE, commonly referred to as IgE). This antibody binds to the M1-prime fragment of the membrane-expressed form of IGHE/IgE. The interaction promotes IGHE/IgE class switching and facilitates the depletion of memory B cells. Given its unique mechanism of action, Quilizumab holds significant potential for advancing research in asthma and other IgE-mediated conditions.

Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ monoclonal antibody that selectively targets the programmed death-1 (PD-1) receptor. This antibody exhibits a high affinity for PD-1 with a dissociation constant (Kd) of 1.72 nM, as determined in HEK293 cells. Cetrelimab effectively inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with half-maximal inhibitory concentrations (IC50) of 111.7 ng/mL and 138.6 ng/mL, respectively. By blocking this pathway, Cetrelimab activates peripheral T cells, leading to enhanced production of key cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α). This immunomodulatory effect contributes to its ability to suppress tumor growth in vivo, making it a valuable tool for cancer immunotherapy research.

Renvistobart is a monoclonal antibody of the immunoglobulin G1-κ class, specifically targeting the T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSIG9 or VSTM3, in Homo sapiens. This antibody binds selectively to the TIGIT receptor, which plays a critical role in the regulation of T cell function and immune response, making it a valuable tool for research in immunology and therapeutic development.

Osemitamab is a monoclonal antibody targeting claudin-18.2, expressed in Chinese Hamster Ovary (CHO) cells engineered with a knockout of the fucosyltransferase 8 gene (FUT8). The absence of FUT8 results in a fucose-deficient antibody, significantly enhancing its Antibody-Dependent Cellular Cytotoxicity (ADCC) capabilities. This product is utilized effectively in combination with Capecitabine and Oxaliplatin for research into gastric (G) and gastroesophageal junction (GEJ) cancers.

Atisnolerbart is a human IgG4 monoclonal antibody specifically designed to target BETVIA, the predominant allergen of birch pollen, known as Betv 1-A. This antibody binds with high specificity to Betv 1-A, potentially mitigating allergic responses. Atisnolerbart is suitable for use in various immunological assays to study birch pollen allergies and may be instrumental in the development of therapeutic approaches for allergen desensitization.

Nirsevimab (MEDI8897) is a recombinant monoclonal antibody designed to target and neutralize human respiratory syncytial virus (RSV). This antibody exhibits potent neutralizing activity against both RSV A and RSV B strains, demonstrated by IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab is an essential tool for research focused on respiratory infections caused by RSV, facilitating the study of virus-host interactions and the evaluation of preventive therapies.

Figitumumab (CP-751871) is a potent, fully human monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF1R). This antibody effectively inhibits the binding of IGF1 to IGF1R, demonstrating an inhibitory concentration (IC50) of 1.8 nM. Designed for high specificity and affinity, Figitumumab is utilized primarily in research focused on the modulation of growth factor signaling pathways.

Veltuzumab (IMMU-106) is a humanized monoclonal antibody targeting CD20, demonstrating a potent efficacy with an EC50 value ranging between 0.08-0.09 μg/mL in the Daudi cell line. This antibody is primarily utilized in oncological research, particularly focusing on non-Hodgkin lymphoma (NHL) and other related cancer studies.

The Anti-CSF3R/G-CSFR Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CSF3R/G-CSFR receptor. This antibody is comprised of a human IgG4SP heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG4 kappa, Isotype Control is recommended. This antibody is ideal for detailed studies on the biological functions and signaling pathways mediated by the CSF3R/G-CSFR receptor, which is pivotal in the regulation of granulocyte production and function.

Rapaprutug is a monoclonal antibody specifically designed to target human KARS1 (lysyl-tRNA synthetase 1), a key enzyme involved in protein synthesis. This antibody effectively inhibits the inflammatory signaling pathways associated with KARS1, thereby diminishing the production and release of pro-inflammatory cytokines. Rapaprutug holds significant potential for advancing research into the mechanisms and treatment of inflammatory diseases.

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a specific N-terminal pyroglutamate amyloid beta (Aβ) epitope. This antibody is designed for use in research focused on early-stage Alzheimer's disease, providing a critical tool for studies aimed at understanding and potentially intervening in the disease's pathogenesis.

Avitotamig is a bispecific antibody designed to target both CD3E and CD33. This dual-targeting molecule is structured as a [H-γ1 _ L-κ-scFv heavy -κ]-dimer, optimizing its ability to engage immune cells and cancer cells simultaneously. This configuration enhances its therapeutic potential in targeting specific leukemic cells while activating cytotoxic T-cells, making it an invaluable tool for research in immunotherapy and oncology.

LY2928057 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting SLC40A1/Ferroportin. This antibody exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa.

Odronextamab is a humanized IgG4 bispecific antibody engineered to target CD20 on B cells and CD3 on T cells. This dual specificity facilitates the direct engagement of T cells and malignant B cells, promoting potent anti-tumor responses. Primarily designed for oncology research, Odronextamab holds significant potential for elucidating the mechanisms of T cell-mediated cytotoxicity in B cell malignancies.

Dovanvetmab, designated as ZTS-00521505, is a recombinant monoclonal antibody of the IgG1-κ isotype. It specifically targets feline interleukin-31 (Felcat IL31), a cytokine implicated in signaling pathways that mediate pruritus and inflammation in cats. This antibody is produced in Chinese Hamster Ovary (CHO) cells, ensuring high fidelity and consistency in antibody structure and function. Dovanvetmab is utilized primarily in veterinary research, focusing on the pathophysiology and potential therapeutic interventions for feline allergic and inflammatory conditions.

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) designed to simultaneously inhibit the activity of PD-1 and CTLA-4 immune checkpoints. By blocking these pathways, Lorigerlimab enhances T-cell mediated immune responses, which are critical in the control and elimination of tumors. This antibody is particularly relevant for studies focused on metastatic castration-resistant prostate cancer (mCRPC), providing a valuable tool for research in immune checkpoint blockade therapies and their role in cancer immunology.

Itepekimab (REGN-3500) is an IgG4 monoclonal antibody that targets interleukin-33 (IL-33). This antibody has demonstrated efficacy in reducing airway inflammation and associated tissue damage in early clinical trials. It holds therapeutic potential for a range of inflammatory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD). The specificity of Itepekimab for IL-33 makes it a promising candidate for further research and development in the management of these diseases.

Ozekibart is a monoclonal antibody specifically targeting TNFRSF10B, a member of the tumor necrosis factor receptor superfamily. This antibody binds selectively to TNFRSF10B, which is implicated in the regulation of apoptosis and cellular signaling in cancer cells. Ozekibart is utilized primarily in research focused on the mechanisms of cell death and survival in oncology, offering potential insights into therapeutic strategies and cancer treatment modalities.

Berlimatoxumab (ASN-2) is a monoclonal antibody designed for experimental research purposes. This antibody targets specific antigens, providing a valuable tool for the investigation of cellular processes and potential therapeutic applications. Its precise specificity and high affinity make it ideal for use in various immunological assays and studies aimed at understanding antigen-antibody interactions within biological systems.

Trovostobart is a monoclonal antibody of the human IgG1 κ isotype, specifically targeting V-set immunoregulatory receptor (VSIR). For experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Lanerkitug is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets CCR8. For experimental control purposes, it is recommended to use Human IgG1 lambda2 as an isotype control. This specificity makes Lanerkitug suitable for research focused on the role of CCR8 in immune responses and potential therapeutic applications.

Domagrozumab is a humanized monoclonal antibody that targets myostatin with a dissociation constant (K_D) of 2.6 pM, indicating high affinity binding. By inhibiting myostatin, a negative regulator of muscle growth, Domagrozumab promotes anabolic activity in muscle tissues. This antibody is primarily utilized in research focused on Duchenne Muscular Dystrophy (DMD), providing a valuable tool for studying the pathology and potential therapeutic interventions for this condition.

Porgaviximab is a monoclonal antibody designed for the study of Ebola virus infections. This antibody targets specific antigens associated with the Ebola virus, making it a valuable tool for researchers investigating the pathogenesis, immune response, and potential therapeutic interventions for this deadly virus. Porgaviximab is suitable for use in a variety of experimental setups, including viral neutralization assays and immunohistochemistry studies.

Pradusinstobart is a human IgG4 κ monoclonal antibody targeting PDCD1 (Programmed Cell Death Protein 1). For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody that specifically targets protein tyrosine kinase 7 (PTK7). This antibody is produced using a Chinese Hamster Ovary (CHO) cell expression system, ensuring high fidelity and stability in the recombinant product. Cofetuzumab is designed for use in research applications focusing on the role of PTK7 in cancer pathogenesis and other related signaling pathways.

Fianlimab (REGN3767) is a human monoclonal antibody designed to specifically bind to the lymphocyte-activation gene 3 (LAG-3) immune checkpoint receptor expressed on T cells. This interaction inhibits the LAG-3 pathway, thereby enhancing T cell function and exhibiting potent anti-tumor activity. Fianlimab is utilized in oncological research to investigate immune checkpoint blockade as a strategy for cancer immunotherapy.

The Anti-TMEFF2 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the TMEFF2 protein. This antibody consists of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Garadacimab (CSL312) represents a pioneering advancement as a fully human IgG4 monoclonal antibody that specifically targets activated factor XII (FXIIa). This unique specificity renders it a valuable tool for investigating the pathophysiology and potential therapeutic interventions for hereditary angioedema.

Vecantoxatug is a humanized monoclonal antibody designed to target the Clostridium tetani toxin (TeNT, neurotoxin). By specifically binding to this toxin, Vecantoxatug inhibits its interaction with cellular receptors, effectively neutralizing its toxic effects. This antibody is particularly valuable for research focused on tetanus, offering potential insights into toxin mechanism and therapeutic interventions.

Ustekinumab is a human monoclonal antibody of the IgG1κ subclass that targets interleukin-12 (IL-12) and interleukin-23 (IL-23). This biologic is engineered to bind specifically to the p40 protein subunit shared by these cytokines, thereby inhibiting their interaction with the IL-12Rβ1 receptor and modulating immune responses involved in inflammatory pathways. Ustekinumab is utilized primarily in the study of immune-mediated disorders and has applications in the research of diseases such as psoriasis, Crohn’s disease, and other chronic inflammatory conditions.

Begelomab (SAND-26) is a murine IgG2b monoclonal antibody specifically targeting DPP-4/CD26. This antibody is utilized in research focused on severe refractory idiopathic inflammatory myopathy, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for this condition.

IMAB027 (ASP1650) is a monoclonal antibody specifically targeting CLDN6 (Claudin 6), a tight junction membrane protein. CLDN6 is aberrantly expressed in a range of human cancers, particularly in ovarian cancers. This antibody has demonstrated potent anti-tumor activity and can induce apoptosis in CLDN6-positive ovarian and testicular cancer cell lines. IMAB027 is utilized primarily in research focused on the pathological roles of CLDN6 in cancer and the therapeutic potential of targeting this protein in oncology.

Pepinemab (VX 15/2503) is a human monoclonal antibody designed to target and neutralize SEMA4D (Signaling Protein 4D), also recognized as CD100. SEMA4D is a critical regulator of neuronal development and is implicated in a range of cellular processes. By inhibiting the activity of SEMA4D, Pepinemab serves as a valuable tool for the investigation of neurodegenerative disorders, including Alzheimer's disease. This antibody is specifically engineered for research applications focused on elucidating the role of SEMA4D in disease pathogenesis and cellular function.

Amrecibart is a human IgG4 κ monoclonal antibody targeting coagulation factor XI. For optimal experimental control, it is recommended to use Human IgG4 kappa as an isotype control.

Tarcocimab (OG1953) is a humanized monoclonal antibody of the IgG1 subtype, specifically targeting VEGFA. This antibody is utilized in research focusing on retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD), offering a valuable tool for investigating the pathological mechanisms and potential therapeutic interventions for these ocular conditions.

Davutamig (REGN-5093) is a human IgG4-kappa monoclonal bispecific antibody designed to target two distinct, non-overlapping epitopes on the MET receptor. This antibody functions as an antineoplastic agent, primarily utilized in cancer research and therapy. Its unique bispecific nature allows for enhanced specificity and efficacy in targeting the MET receptor, a critical player in the pathology of various cancers.

Plutavimab is a human IgG1-κ monoclonal antibody specifically designed to target the receptor-binding domain (RBD) of the Spike (S) glycoprotein of SARS-CoV-2. This antibody binds with high specificity and affinity, potentially neutralizing the virus by preventing its entry into host cells. Plutavimab is suitable for research applications focused on the study of viral entry mechanisms, virus-host interactions, and the development of therapeutic strategies against SARS-CoV-2.

Enuzovimab (HFB-30132A) is a monoclonal antibody specifically developed to target the SARS-CoV-2 Omicron variant. It exhibits high-affinity binding to the spike (S) protein of the virus, offering potential utility in therapeutic interventions against this strain.

The Anti-Siglec-15/CD33L3 Antibody is derived from human sources and expressed in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets Siglec-15, also known as CD33L3, a sialic acid-binding Ig-like lectin involved in immune regulation. Comprising a human IgG1 heavy chain and a human lambda light chain, this antibody has a predicted molecular weight of 146.02 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This product is essential for research focusing on the role of Siglec-15 in immune responses and its potential implications in therapeutic interventions.